Mild Cognitive Impairment: Clinical Trials

23 trials for Mild Cognitive Impairment, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

15 completed, 3 active not recruiting, 2 unknown, 1 recruiting. 23 Phase 3, 9 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 323Completed 15, Active not recruiting 3, Unknown 2, Recruiting 1, Terminated 1, Withdrawn 1
Phase 29Completed 5, Active not recruiting 2, Unknown 2

Follow Mild Cognitive Impairment: new trials by email Literature Review of Mild Cognitive Impairment trials Research Report on Mild Cognitive Impairment

Trials (filtered) newest first · largest first

All 23 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)
Mazdutide, Placebo - Dementia, Mild, Mild Cognitive Impairment
Phase 3RecruitingThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School4202025-09-272026-09-02
Study on Ginkgo Biolba Extract Fifty and Mild Cognitive Impairment Associated With CSVD
Ginkgo biloba extract 50 dropping pills, Ginkgo biloba extract Ginkgo biloba extract 50 Drops simulant - Mild Cognitive Impairment
Phase 2 / Phase 3Active not recruitingBeijing Tiantan Hospital1442024-09-272026-10-08
Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment
Precision Medicine Approach, Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises, Standard-of-Care - Mild Cognitive Impairment, Dementia, Mild
Phase 3CompletedAlzheimer's Prevention and Reversal Project, Inc.732023-07-312026-02-18
ACHIEVE Brain Health Follow-Up Study
Hearing intervention, Successful aging/delayed hearing intervention - Aging, Cognitive Decline
Phase 3Active not recruitingJohns Hopkins University6292023-01-122026-07-21
Metformin in Alzheimer's Dementia Prevention
Placebo oral tablet, extended release metformin - Mild Cognitive Impairment
Phase 2 / Phase 3Active not recruitingColumbia University3262021-03-222026-08-11
Dapagliflozin Effect in Cognitive Impairment in Stroke Trial
Dapagliflozin 10mg Tab, Statins (Cardiovascular Agents), Platelet Antiaggregant - Stroke, Ischemic, Mild Cognitive Impairment
Phase 2 / Phase 3UnknownJaime Daniel Mondragon2702020-08-012022-10-04
Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease
Placebo Oral Tablet, AGB101 220 mg tablet - Mild Cognitive Impairment, Prodromal Alzheimer's Disease
Phase 2 / Phase 3CompletedAgeneBio1642018-12-132024-05-17
Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type
Renew NCP-5 - Alzheimer Disease, Cognitive Dysfunction
Phase 3CompletedRenew Research, LLC1902018-11-122022-05-11
Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke
MMH-MAP, Placebo - Mild Cognitive Impairment, Ischemic Stroke
Phase 3CompletedMateria Medica Holding2762018-10-192021-02-23
The Combination of Donepezil and Cognitive Training for Treating Alcohol Use Disorder
Donepazil - Alcohol Use Disorder, Mild Cognitive Impairment
Phase 2 / Phase 3CompletedVA Connecticut Healthcare System152018-08-172020-03-24
Molecular Cerebral Imaging in Incipient Dementia (MCI-ID) II
Amyloid imaging, FDG-PET - Mild Cognitive Impairment
Phase 3WithdrawnUniversity of California, Los Angeles2018-06-012018-10-15
The Healthy Patterns Sleep Study
Attention-Control Condition, Timed Activity Intervention - Dementia, Alzheimer Disease
Phase 3CompletedUniversity of Pennsylvania4212016-05-012024-07-26
Investigating the Clinical Consequences of Flutemetamol-PET-scanning
Flutemetamol (Vizamyl) - Mild Cognitive Impairment, Alzheimer's Disease
Phase 3TerminatedUniversity of Zurich112015-05-012020-01-21
Effects of Multimodal Cognitive Enhancement Therapy (MCET) for Ealy Dementia
Period I MCET (8 wks), Washout (4 wks), Period II MCET (8 wks) - Mild Cognitive Impairment, Dementia, Mild
Phase 3CompletedKi Woong Kim642014-02-012015-07-28
DIetary Supplements, Executive funcTions and Vitamin D (DIET-D)
Lecitone®Se-Vitamin D3, Placebo - Mild Cognitive Impairment
Phase 2 / Phase 3UnknownUniversity Hospital, Angers1602012-11-012012-10-16
A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
florbetapir (18F) - Alzheimer's Disease, Mild Cognitive Impairment
Phase 2 / Phase 3CompletedAvid Radiopharmaceuticals482012-10-012013-09-19
Efficacy of Ubiquitous SR-based Memory Advancement and Rehabilitation Training (U-SMART)
Phase I U-SMART (4 wks), Washout (2 wks), Phase II U-SMART (4 wks) - Mild Cognitive Impairment
Phase 3CompletedSeoul National University Bundang Hospital502012-08-012016-04-20
Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images
[18F]Flutemetamol - Alzheimer's Disease, Mild Cognitive Impairment
Phase 3CompletedGE Healthcare2762012-07-012014-01-24
Effects of Dietary Interventions on the Brain in Mild Cognitive Impairment (MCI)
caloric restriction, omega-3 supplementation, resveratrol supplementation - Mild Cognitive Impairment
Phase 2 / Phase 3CompletedCharite University, Berlin, Germany3302010-08-012017-07-28
Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease
Flutemetamol (18F) Injection - Mild Cognitive Impairment, Alzheimer's Disease
Phase 3CompletedGE Healthcare3652009-12-012014-09-11

Showing 20 of 23. Sign in to see all of them.

Narrower conditions

Cognitive Dysfunction (23)  ·  Alzheimer Disease (11)  ·  Dementia (7)  ·  Lymphoma, Follicular (3)  ·  Dementia, Vascular (2)  ·  Ischemic Stroke (2)  ·  Alcoholism (1)  ·  Anomia (1)  ·  Chronobiology Disorders (1)  ·  Communication Disorders (1)  ·  Depression (1)  ·  Depressive Disorder, Major (1)  ·  Diabetes Mellitus, Type 2 (1)  ·  Disorders of Excessive Somnolence (1)  ·  Frontotemporal Dementia (1)

Broader conditions

Cognition Disorders (23)  ·  Mental Disorders (23)  ·  Neurocognitive Disorders (22)  ·  Brain Diseases (16)  ·  Central Nervous System Diseases (16)  ·  Nervous System Diseases (16)  ·  Neurodegenerative Diseases (11)  ·  Tauopathies (11)  ·  Dementia (8)  ·  Cardiovascular Diseases (4)  ·  Cerebrovascular Disorders (4)  ·  Neurologic Manifestations (4)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Signs and Symptoms (4)  ·  Vascular Diseases (4)

Interventions

flutemetamol (3)  ·  Aspirin (1)  ·  Atorvastatin (1)  ·  Biguanides (1)  ·  Bromocriptine (1)  ·  Caloric Restriction (1)  ·  Cardiovascular Agents (1)  ·  Clopidogrel (1)  ·  Cognitive Training (1)  ·  Donepezil (1)  ·  Escitalopram (1)  ·  Exercise (1)  ·  Hormones (1)  ·  Hydroxymethylglutaryl-CoA Reductase Inhibitors (1)  ·  Hypoglycemic Agents (1)

Sponsors

GE Healthcare (2)  ·  AgeneBio (1)  ·  Alzheimer's Prevention and Reversal Project, Inc. (1)  ·  Avid Radiopharmaceuticals (1)  ·  Beijing Tiantan Hospital (1)  ·  Charite University, Berlin, Germany (1)  ·  Columbia University (1)  ·  Jaime Daniel Mondragon (1)  ·  Johns Hopkins University (1)  ·  Ki Woong Kim (1)  ·  Materia Medica Holding (1)  ·  New York State Psychiatric Institute (1)  ·  North China Pharmaceutical Group Corporation (1)  ·  Renew Research, LLC (1)  ·  Seoul National University Bundang Hospital (1)

Countries

United States (10)  ·  China (3)  ·  South Korea (2)  ·  Canada (1)  ·  France (1)  ·  Germany (1)  ·  Ireland (1)  ·  Japan (1)  ·  Mexico (1)  ·  Russia (1)  ·  Singapore (1)  ·  Switzerland (1)

Top investigators

Ki Woong Kim, M.D., Ph.D. (2)  ·  Agnes Floeel, Prof. (1)  ·  Billy Tally (1)  ·  Christoph Hock, MD, Prof. (1)  ·  Dale Bredesen, MD (1)  ·  Daniel Silverman, MD, Ph.D. (1)  ·  Davangere Devanand, M.D. (1)  ·  Frank R Lin, MD, PhD (1)  ·  Gregory Pelton, M.D. (1)  ·  Jinzhou Tian, MD,PhD (1)  ·  Josef Coresh, MD, PhD (1)

Results publications

PMID 20204386, PMID 23040716, PMID 26433119, PMID 26559790, PMID 26912492, PMID 27037094, PMID 27511061, PMID 28095900, PMID 28326010, PMID 28587629, PMID 28596794, PMID 28950419, PMID 29016744, PMID 29336496, PMID 29371333, PMID 29379114, PMID 29446769, PMID 29573529, PMID 31236801, PMID 31248555, PMID 31535829, PMID 32115470, PMID 32144994, PMID 32178931, PMID 32317958, PMID 32352644, PMID 32559474, PMID 32854852, PMID 33030307, PMID 33282811, PMID 33853394, PMID 33894597, PMID 34344312, PMID 34813630, PMID 35351181, PMID 37203336

NIH funding

R01AG027156 (1), R01AG048349 (1), R01AG061091 (1), R01AG062624 (1), R01AG076518 (1), R01NR015226 (1), R56AG055416 (1)